Eventide Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Eventide Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-61,081	Closed	-$5.85M	–	271
2025 Q3	$5.85M	Buy	+61,081	New	+$3.9M	0.1%	140
2018 Q1	–	Sell	-8,600	Closed	-$1.17M	–	146
2017 Q4	$1.17M	Sell	8,600 -4,600	-35%	-$698K	0.06%	123
2017 Q3	$2.14M	Hold	13,200	–	–	0.12%	103
2017 Q2	$1.98M	Hold	13,200	–	–	0.12%	97
2017 Q1	$2.06M	Hold	13,200	–	–	0.14%	92
2016 Q4	$2.75M	Hold	13,200	–	–	0.18%	87
2016 Q3	$3.02M	Hold	13,200	–	–	0.18%	84
2016 Q2	$2.72M	Hold	13,200	–	–	0.17%	91
2016 Q1	$3.35M	Hold	13,200	–	–	0.19%	86
2015 Q4	$4.53M	Buy	13,200 +4,430	+51%	+$1.33M	0.23%	90
2015 Q3	$2.23M	Buy	8,770 +2,639	+43%	+$754K	0.13%	97
2015 Q2	$1.72M	Buy	+6,131	New	+$1.89M	0.09%	101

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Eventide Asset Management's CDTX Position: Q4 2025 in Review

Eventide Asset Management sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 61,081 shares — an estimated $5.85M sold.

Eventide Asset Management first reported a position in CDTX in Q2 2015 and held it in 12 quarters. The position peaked at $5.85M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

Eventide Asset Management reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
Eventide Asset Management sold 61,081 Cidara Therapeutics shares in Q4 2025, an estimated $5.85M.
Eventide Asset Management first reported a position in Cidara Therapeutics in Q2 2015 and held it in 12 quarters.
Eventide Asset Management's Cidara Therapeutics position peaked at $5.85M in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.